Form 4: Ironwood Pharmaceuticals Director Alexander Denner Boosts Stake with Restricted Stock Grant

Alexander J. Denner, a Director and 10% owner of Ironwood Pharmaceuticals Inc., acquired 45,000 shares of Class A Common Stock through a restricted stock grant, increasing his direct beneficial ownership.

Summary

• Alexander J. Denner, a Director and 10% owner of Ironwood Pharmaceuticals Inc. (IRWD), acquired 45,000 shares of Class A Common Stock on June 10, 2025.
• The acquisition was a grant of restricted stock, with a reported price of $0 per share, pursuant to the company's Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
• Following this transaction, Dr. Denner directly beneficially owns 211,769 shares of Class A Common Stock.
• Additionally, Dr. Denner indirectly beneficially owns 16,390,000 shares through Sarissa Capital Management LP and its associated funds, where he serves as Chief Investment Officer and control party.
• The restricted stock grant vests in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Sentiment

Score: 7

Explanation: The acquisition of 45,000 shares by a director and 10% owner, Alexander J. Denner, through a restricted stock grant, indicates continued alignment of interests with shareholders and confidence in the company's future, despite being part of a compensation policy.

Positives

• The acquisition of 45,000 shares by a director and significant shareholder, Alexander J. Denner, aligns his interests further with those of other shareholders.
• The grant of restricted stock at a $0 price indicates it is part of a compensation package, which is a common practice for non-employee directors and can be seen as a commitment to the company's long-term performance.

Future Outlook

The 45,000 restricted shares granted to Dr. Denner are scheduled to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year, indicating a future milestone for this specific grant.

Management Comments

• Alexander Denner, as Chief Investment Officer of Sarissa Capital Management LP, disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction in the pharmaceutical industry, reflecting a director's compensation and ownership stake. Such filings provide transparency into management and significant shareholder holdings, which can be a factor in investor sentiment.

Corporate Governance

Related Party Transactions

• Alexander J. Denner's indirect beneficial ownership of 16,390,000 shares is through Sarissa Capital Management LP and its associated funds, where Dr. Denner is the Chief Investment Officer and managing member/general partner. This constitutes a related party transaction due to his control and influence over these entities.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal, indicating management's confidence in the company's future prospects and aligning their interests with long-term shareholder value.

Next Steps

• The restricted stock grant of 45,000 shares will vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Key Dates

Keywords

Ironwood Pharmaceuticals, IRWD, Alexander Denner, Sarissa Capital Management, SEC Form 4, Insider Transaction, Stock Grant, Beneficial Ownership, Director Compensation, Pharmaceuticals